Although nearly 10% of patients experience profound vasodilatory shock after cardiopulmonary bypass, some patients remain refractory to traditional resuscitation. Among this subset are patients who have inappropriately low levels of endogenous vasopressin. Thus, vasopressin replacement is an intuitively attractive intervention. The purposes of this review are to outline the pathophysiology of vasodilatory shock after cardiopulmonary bypass, to discuss the physiological role of endogenous vasopressin, to explore the clinical basis for vasopressin replacement, and to review the pharmacology and dosing guidelines.
Skip Nav Destination
Cardiac Surgical Care| July 01 2002
Vasopressin in the Cardiac Surgery Intensive Care Unit
Tracy N. Albright, RN, CCRN;
Michael A. Zimmerman, MD;
Am J Crit Care (2002) 11 (4): 326–330.
- Views Icon Views
- Share Icon Share
Tracy N. Albright, Michael A. Zimmerman, Craig H. Selzman; Vasopressin in the Cardiac Surgery Intensive Care Unit. Am J Crit Care 1 July 2002; 11 (4): 326–330. doi: https://doi.org/10.4037/ajcc2002.11.4.326
Download citation file: